AbbVie vs Galderma

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval is based on Phase 3 TEMPO data showing significant improvements in daily functioning, increased "on" time without troublesome dyskinesia, and a favorable safety profile. AbbVie expects to make JUVMO available to U.S. patients in October 2026.

• The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease.
• The approval was supported by Phase 3 TEMPO clinical trial data (TEMPO-1, TEMPO-2, TEMPO-3, and TEMPO-4).
• JUVMO is taken once daily with or without levodopa therapy and is available in 5 mg, 10 mg, and 15 mg tablets plus a Titration Pack containing 0.25 mg and 1 mg tablets.

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On September 22, 2026, AbbVie's Executive Vice President, General Counsel and Secretary Perry Siatis testified before the U.S. Trade Representative (USTR) in a Section 301 investigation into Germany. He argued that Germany's pharmaceutical pricing and reimbursement policies undervalue innovation, harm future R&D, and place an unfair cost burden on the U.S. healthcare system. Germany recently increased mandatory manufacturer rebates from 7% to 15.5%, which combined with other measures can reduce a medicine's value by nearly 54%. AbbVie seeks a constructive, fair global agreement on equitable investment in innovation.

• On September 22, 2026, AbbVie's Perry Siatis testified before the USTR in a Section 301 investigation into Germany.
• Germany increased mandatory manufacturer rebates from 7% to 15.5%.
• The cumulative effect of German price controls can reduce an innovative medicine's value by nearly 54%.

Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older

Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.

EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis

Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.

• Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
• At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
• The findings were presented at the EADV 2026 Congress in Vienna, Austria, with the oral presentation scheduled for Thursday, October 1, 2026.

Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies

Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.